Stock Ratings / Health Care / WHWK / insiders

ZNTL (39) YARW (41) ADCT (33) SION (38) ⌘ Pro Terminal →

Whitehawk Therapeutics Inc. (WHWK) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.24 -1.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.22

Whitehawk Therapeutics Inc. (WHWK) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $188.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on WHWK Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is WHWK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Whitehawk Therapeutics Inc. (NASDAQ: WHWK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $3.24 (-1.82% 1D, market cap $188.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, WHWK ranks #903 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does WHWK compare to ZNTL and YARW in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), WHWK carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 89.4%, and ROIC of -35.0%. By comparison, ZNTL (Zentalis Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $188.4M) and YARW (Yarrow Bioscience Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $186.1M). Among the 5-stock peer group, WHWK leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for WHWK?

▼

Per WHWK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001422142), Whitehawk Therapeutics Inc. generated $7.1M in revenue (-72.5% YoY), -$20.6M in net income, and -$98.0M in free cash flow against $150.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.22 (-0.52%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for WHWK)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY WHWK SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 36% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (25% of score)

Altman Z-Score 3.11 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.52-17.9% Next Q

Q2 (-2Q)

Grade E$2.89+11.1% Next Q

Q3 (-1Q)

Grade E$3.21+0.9% Next Q

Current

Grade E$3.24-10% Hist 90D α

Trajectory: E (36) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a WHWK Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While WHWK currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.86) and Max Pain ($3.40) forces dealer call-delta covering toward $5.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $WHWK• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “WHWK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

WHWK Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (WHWK)

No recent open-market Form 4 cluster sales or emergency dumps flagged on WHWK. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring WHWK)

✓Walkthrough of WHWK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

WHWK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.20%▼ DESCENDING CHANNEL

2026-10-30O $3.29H $3.37L $3.20C $3.24VOL 153.3K

RES: $4.85SUP: $2.78SMA50: $3.86SMA200: $3.84

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

WHWK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 WHWK Butterfly Map → + Track WHWK →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on WHWK today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for WHWK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for WHWK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (WHWK)

Health Care Rank #903 of 1016 ⚔️ ZNTL vs WHWK Full Matrix →

1. Head-to-Head Health Care Peer Comparison (WHWK vs. ZNTL, YARW, ADCT, SION)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Whitehawk Therapeutics Inc. (WHWK) ranks #903 by composite RQD confidence (28/100, grade E) and #586 by equity capitalization ($188.1M). Within this direct 5-issuer industry benchmark cohort, WHWK leads on earnings valuation at N/A trailing P/E, while SION leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. YARW currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with WHWK at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
WHWK ACTIVE Whitehawk Therapeutics Inc.	E	28/100	—	89.4%	-35.0%	-1.82%	$188.1M	Benchmark Subject
ZNTL Zentalis Pharmaceuticals Inc.	D-	39/100	—	—	-35.0%	-1.51%	$188.4M	/zntl-vs-whwk →
YARW Yarrow Bioscience Inc.	D-	41/100	—	—	-35.0%	-0.50%	$186.1M	/yarw-vs-whwk →
ADCT ADC Therapeutics SA	E	33/100	—	92.9%	-35.0%	+2.69%	$190.2M	/adct-vs-whwk →
SION Sionna Therapeutics Inc.	D-	38/100	—	—	-28.3%	-3.25%	$180.8M	/sion-vs-whwk →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001422142

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Whitehawk Therapeutics Inc. (WHWK) reported GAAP revenue of $7.1M (-72.5% vs. FY2024 revenue of $26.0M , and -70.7% cumulative change since FY2023) , GAAP net income of -$20.6M, operating cash flow of -$97.4M, and free cash flow of -$98.0M (-60.1% YoY). On the balance sheet, WHWK closed FY2025 with $150.8M in total assets against $0 in total debt (Altman Z-Score: 3.11, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.1M	-$20.6M	-$97.4M	-$98.0M	$150.8M	—
FY2024 (FY)	2024-12-31	$26.0M	-$63.7M	-$59.5M	-$61.2M	$70.3M	—
FY2023 (FY)	2023-12-31	$24.4M	-$65.8M	-$59.7M	-$59.7M	—	—

3. WHWK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is WHWK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does WHWK compare to ZNTL and YARW in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for WHWK?

Where is WHWK trading relative to its 50-day, 200-day, and 52-week technical levels?

WHWK last traded at $3.24 (-1.82% on volume of 153,351 shares), positioning the stock -16.06% below its 50-day simple moving average ($3.86) and -15.62% below its 200-day simple moving average ($3.84). Across its 52-week range of $1.97 to $5.50, WHWK sits at the 36.0% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.83 to $3.65).

WHWK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are WHWK insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies WHWK leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: WHWK RQD Cockpit WHWK 12M Forecast WHWK Earnings & Move WHWK Dividends & DRIP WHWK Insiders & 13F WHWK Whale Options WHWK Profit Sankey WHWK News & Why

ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

WHWK — Whitehawk Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:37Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, WHWK scores 28 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

Fundamental Cash Engine: 4 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, the core earning-power test is failing: the business is not currently generating returns on invested capital or free cash flow to shareholders.
Whale 13F Flow: 6 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is weak, indicating limited institutional sponsorship signals in the source data.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, which an investor should weigh as a negative signal on insider conviction.
Macro Regime Fit: 8 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. This is a neutral-to-weak market-sensitivity profile rather than a defensive one.
Forensic Balance Sheet: 7 / 20. Per the Roarable RQD rating, the Altman Z-Score is 3.11, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. The Altman reading sits in a range the rating treats as not distressed, but the weak Piotroski score signals deteriorating fundamental quality.

Taken together, the rating frames WHWK as a stock where the cash-generation and insider-conviction pillars are the largest drags. The upside case rests on a turnaround in operating economics, which the source data does not show yet. The valuation tradeoff is that a $188.1M market cap is being carried against negative operating margins, so price is not supported by current cash earnings. This is an analytical read of the rating's components, not personalized advice.

Business

Whitehawk Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the company profile. Per the SEC financials, FY 2025 revenue was $7.1M, down from $26.0M in FY 2024. The source data does not describe specific products, customers, or the monetization model beyond this sector classification.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$7.1M	$-114.4M	$-20.6M	N/A	$-98.0M	$37.6M	N/A
FY 2024	$26.0M	$-67.5M	$-63.7M	N/A	$-61.2M	$28.7M	N/A
FY 2023	$24.4M	$-71.9M	$-65.8M	N/A	$-59.7M	N/A	N/A

Per the market data, gross margin is 89.4% while operating and net margins are both -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 3.11 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Per the SEC financials, free cash flow was negative in every reported period, and cash declined from $37.6M at FY 2025 relative to the FY 2024 reading of $28.7M, which rose. The profitability picture is loss-making throughout the reported window.

Recent Catalysts & News Wire Analysis

Per the recent news wire, the items are headline-level only. A MarketBeat item reports a consensus target price of $8.33 according to brokerages, flagged YELLOW. A Form 4 filing by director and CEO David James Lennon is noted, flagged YELLOW. A MarketBeat item reports the stock fell 4.6%, flagged RED under RISK WATCH. Other items are Yahoo! Finance Canada seasonal chart pages on Fennec Pharmaceuticals and Surrozen, plus a TradingKey dividend-screen article, all flagged YELLOW. Per the Butterfly Supply-Chain Graph, there are no proprietary signals and no supply-chain links recorded.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply_chain is NONE and butterfly_links is empty. The source data contains no upstream or downstream dependencies, sector correlation mapping, or bottleneck analysis. A prospective investor should note that the graph cannot identify second-order ripples from this data alone.

Open Questions

What specific products or pipeline assets generate the FY 2025 revenue of $7.1M, and what drove the decline from $26.0M?
What is the cash runway given FY 2025 free cash flow of $-98.0M against $37.6M of cash?
Why are EPS, debt, and FY 2023 cash not reported in the financial statements?
What is the basis for the consensus target price of $8.33 cited in the news wire, given that analyst data is absent?
What institutional and insider holdings underlie the 13F and Form 4 signals behind the RQD pillar scores?

WHWK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Whitehawk Therapeutics Inc. (WHWK) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to WHWK Debate Forum (3) ↓

🟡 MARKET WIRE MarketBeat • 6h ago

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 9h ago

Form 4 Whitehawk Therapeutics Inc: David James Lennon (Director, CEO) For: 15 September

Investing.com Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 12h ago

Fennec Pharmaceuticals Inc. (FENC) Seasonal Returns Chart

Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 15h ago

Whitehawk Therapeutics (NASDAQ:WHWK) Stock Falls 4.6% - Here's What Happened

MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 18h ago

Surrozen, Inc. (SRZN) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 21h ago

High Dividend Yield Stocks for Income

TradingKey report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Whitehawk (WHWK) Stock Price: Up +1.50% Today, Target $3.55 2026-10-28 - VWAP Deviation

https://www.dars.gov.et/ report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Whitehawk Therapeutics, Inc. (WHWK) - What Are Analysts Saying About This Stock?

MarketBeat report covering Whitehawk Therapeutics Inc. (WHWK) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

WHWK Bull vs. Bear Conversation Board — What's Your Call at $3.24?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON WHWK 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.85 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is WHWK (E • RQD 28/100) a Buy at $3.24?

Welcome to the WHWK (Whitehawk Therapeutics Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.59 (-20.1%)

Spot @ $3.24

Pump the brakes on WHWK — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on WHWK, but look at what you are paying: current EV/EBITDA multiples with 89.4% gross margins. Unless Whitehawk Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.15 (+28.1%)

Spot @ $3.24

WHWK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on WHWK, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.24 (52-wk range $1.97 - $5.50), any beat on forward guidance forces shorts and underweight funds to chase.